At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 170 enrolled
Drug / intervention
Aripiprazoledrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Multicenter Study Evaluating the Safety and Tolerability of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder
Otsuka Pharmaceutical Development & Commercialization, Inc.·interventional·Posted Aug 15, 2011·Updated Oct 7, 2021
In Brief
A Phase 3 clinical trial evaluating Aripiprazole for Tourette's Disorder. Completed, enrolled 170 participants across 80 sites in 10 countries.
Detailed Summary
The goal of the current trial is to obtain long term efficacy, safety and tolerability data of once weekly aripiprazole in children and adolescents with Tourette's Disorder.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTourette's Disorder
CountriesBulgaria, Canada, Germany, Hungary, Mexico, Romania, South Korea, Taiwan, Ukraine, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedAug 2011
Enrollment StartOct 2011
Primary CompletionMar 2014
TodayJul 2026
First PostedAug 15, 2011
Enrollment StartOct 19, 2011
Primary CompletionMar 13, 2014
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 14.9 years ago
Interventions
Aripiprazoledrug
Aripiprazole tablets orally once daily.